|1.||Wilding, George: 3 articles (12/2005 - 11/2002)|
|2.||Marnocha, Rebecca: 2 articles (12/2005 - 06/2003)|
|3.||Liu, Glenn: 2 articles (12/2005 - 06/2003)|
|4.||Rosowsky, Andre: 2 articles (05/2004 - 04/2003)|
|5.||Queener, Sherry F: 2 articles (05/2004 - 04/2003)|
|6.||Lassiter, Lance K: 1 article (03/2008)|
|7.||Tummala, Mohan K: 1 article (03/2008)|
|8.||Hussain, Maha H: 1 article (03/2008)|
|9.||Stadler, Walter M: 1 article (03/2008)|
|10.||Petrylak, Daniel P: 1 article (03/2008)|
11/01/2002 - "Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group."
11/01/2002 - "Patients with previously-treated, advanced urothelial carcinoma were treated with oral piritrexim at a dose of 25 mg three times daily for 5 consecutive days each week for 3 consecutive weeks followed by a 1-week rest period. "
03/01/2008 - "We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial carcinoma and who proved nonresponsive to standard chemotherapy. "
03/01/2008 - "Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy."
11/01/1999 - "In March 1995, ILEX acquired an exclusive, worldwide license to patents held by Burroughs Wellcome covering the composition and use of piritrexim for all cancer indications. "
12/01/2005 - "Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors."
12/01/2005 - "The combination of piritrexim and gemcitabine was determined to be tolerable in heavily pretreated patients for use in solid tumors."
06/01/2003 - "Piritrexim is a new antifolate that has shown activity in methotrexate-resistant tumors. "
11/01/1999 - "Due to its potentially superior properties to those of methotrexate, it was expected that piritrexim would be active in certain methotrexate-resistant tumors. "
|4.||Urinary Bladder Neoplasms (Bladder Cancer)
11/01/1999 - "ILEX conducted phase II clinical trials in the US and Europe with piritrexim in bladder cancer patients; however, development for this indication was discontinued in the third quarter of 1998 due to lack of efficacy. "
11/01/1999 - "In published phase II studies, piritrexim demonstrated objective response rates ranging from 23 to 75% in patients with advanced bladder cancer who failed a standard first-line chemotherapy regimen. "
|5.||HIV Infections (HIV Infection)
04/24/2003 - "As part of an ongoing effort to discover novel small-molecule antifolates combining the enzyme-binding species selectivity of trimethoprim (TMP) with the potency of piritrexim (PTX), 10 previously unreported 2,4-diamino-5-(2'-methoxy-5'-substituted)benzylpyrimidines (2-11) containing a carboxyl group at the distal end of the 5'-substituent were synthesized and tested as inhibitors of dihydrofolate reductase (DHFR) from Pneumocystis carinii (Pc), Toxoplasma gondii (Tg), and Mycobacterium avium (Ma), three of the opportunistic pathogens frequently responsible for life-threatening illness in people with impaired immune systems as a result of HIV infection or immunosuppressive chemotherapy. "
|3.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|6.||Thymidine Monophosphate (TMP)
|7.||Folic Acid Antagonists
|1.||Drug Therapy (Chemotherapy)